Cleveland Clinic’s preventive breast cancer vaccine growth takes step forward

Cleveland Clinic Innovations has created a spin-off company to develop a preventive breast cancer vaccine based on research through Cleveland Clinic’s Lerner Research Company. The brand new company, Shield Biotech, will complete preclinical development and seek permission from the FDA to test the shot as an investigational new drug within proof-of-concept, first-in-human clinical trials. The trials are expected to start within 2 yrs and will take about three years to accomplish. “The mission of Shield Biotech will be to convert the scientific research on a breast cancer vaccine, led by Vincent Tuohy, Ph. D., at Cleveland Center, into a viable preventive alternative for the patients who may benefit, ” said Thomas Graham, MD, Cleveland Clinic’s Chief Innovation Officer. “We believe that the vaccine has the possible to stop the more lethal forms of breast cancer, as well as inhibiting the recurrence of triple-negative breast cancer in women once they have recovered from their initial disease. ” Initially, Shield Biotech will extend the development to the clinical stage where the vaccine will be tested in 2 Phase I clinical trials as part of the process to obtain FDA approval. These trials are designed to establish the security of the vaccine in women and to characterize and optimize the immune response. Experts at Cleveland Clinic’s Lerner Study Institute found that a single vaccination could pr...
Source: My Irritable Bowel Syndrome Story - Category: Other Conditions Authors: Tags: IBS News Source Type: blogs